• Who We Serve
    • Hospitals
    • Community Health Centers
    • Contract Pharmacies
  • Solutions
    • Split Billing
    • CompliancePlus
    • Contract Pharmacy
    • Specialty Contract Pharmacy
    • Enterprise Backbone
  • About RxS
    • Company Overview
    • Executive Leadership
    • Board of Directors
  • News & Events
    • News
      • Blog
      • Clinical Insights
      • 340B Insider
      • Press Releases
    • Events
  • Connect With Us
    • Contact Us
    • Contact Support
  • Contact Support
  • Portal Login
  • Contact Support
  • Portal Login
  • Who We Serve
    • Hospitals
    • Community Health Centers
    • Contract Pharmacies
  • Solutions
    • Split Billing
    • CompliancePlus
    • Contract Pharmacy
    • Specialty Contract Pharmacy
    • Enterprise Backbone
  • About RxS
    • Company Overview
    • Executive Leadership
    • Board of Directors
  • News & Events
    • News
      • Blog
      • Clinical Insights
      • 340B Insider
      • Press Releases
    • Events
  • Connect With Us
    • Contact Us
    • Contact Support

FDA approves $84,000 a treatment hepatitis C drug

    FDA approves $84,000 a treatment hepatitis C drug

    Posted on December 17, 2013 by Tim Vroman - News

    By Associated Press

    Posted: December 7, 2013 – 9:30 am ET
    Tags: Associated Press (AP), Pharmaceuticals, Physicians, U.S. Food and Drug Administration (FDA)

     

    U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.

    The Food and Drug Administration said Friday it approved the pill Sovaldi in combination with older drugs to treat the main forms of hepatitis C that affect U.S. patients.

    Read More:

Categories

  • 340B Insider
  • Blog
  • Clinical Insights
  • Events
  • News
  • Press Releases

Archives

What clients say about RxStrategies:

  • "Due to RxStrategies' comprehensive solutions specifically for FQHCs to manage a compliant 340B program, our available discounts from the 340B program tripled in the rural areas where we operate in partnership with contract pharmacies."

  • "Communication throughout the transition process from another TPA was stellar. The RxStrategies team was there for us at a moment’s notice."

  • "The exemplary customer service RxStrategies' sales department and account managers provide is a key component of our strong partnership."

  • Who We Serve
  • Solutions
  • About RxS
  • News
  • Events
  • Contact Us
  • Contact Support
  • Portal Login

Want to receive updates straight to your inbox?

Sign up
© 2021 RxStrategies, Inc. All Rights Reserved. Privacy Statement